About

Dr. Ferkol is a pediatric pulmonologist with over thirty years of experience, who has special expertise in suppurative lung diseases, like cystic fibrosis, primary ciliary dyskinesia, and non-cystic fibrosis bronchiectasis. An American Lung Association Edward Livingston Trudeau Scholar and recipient of the Cystic Fibrosis Foundation LeRoy Matthew’s Physician-Scientist Award and PCF Foundation Golden Cilium Award, his research has largely focused of genetic and molecular factors that contribute to chronic airway infection, inflammation, and epithelial injury, with nearly thirty-years of continuous funding from the National Institutes of Health. He currently co-leads the Genetic Disorders of Mucociliary Clearance Consortium, an established, multicenter collaborative that is defining the genetics, pathogenesis, and clinical manifestations of inherited, suppurative lung diseases. He has served on numerous international review groups and study sections, and written or co-authored over 200 original articles, scholarly reviews, and book chapters. Finally, Dr. Ferkol is a past-president of the American Thoracic Society, an international professional organization of over 15,000 members worldwide, only the second pediatrician to serve in this capacity during the 120-year history of the organization.

Selected research publications include:

• Ferkol T, Schraufnagel D. The global burden of respiratory disease. Ann Am Thorac Soc. 2014;11:404-6. PMID: 24673696.
• Davis SD, Ferkol TW, Rosenfeld M, et al. Clinical features of childhood primary ciliary dyskinesia by genotype and ultrastructural phenotype. Am J Respir Crit Care Med. 2015;191:316-24. PMID: 25493340; PMCID: PMC4351577.
• Leigh MW, Ferkol TW, Davis SD, et al. Clinical features and associated likelihood of primary ciliary dyskinesia in children and adolescents. Ann Am Thorac Soc 2016;13:1305-13. P PMID: 27070726; MCID: PMC5021075.
• Keller RL, Feng R, DeMauro SB, et al. Bronchopulmonary dysplasia and perinatal characteristics predict 1-year respiratory outcomes in newborns born at extremely low gestational age: a prospective cohort study. J Pediatr. 2017;187:89-97.e3. PMID: 28528221; PMCID: PMC5533632.
• Pittman JE, Wylie KM, Akers K, et al. Association of antibiotics, airway microbiome, and inflammation in infants with cystic fibrosis. Ann Am Thorac Soc. 2017;14:1548-55. PMID: 28708417;PMCID: PMC5718571.
• Ferkol TW, Farber HJ, La Grutta S, et al. Electronic cigarette use in youths: a position statement of the Forum of International Respiratory Societies. Eur Respir J. 2018;30;51(5):1800278. PMID: 29848575.
• Davis SD, Rosenfeld M, Lee HS, et al. Primary ciliary dyskinesia: longitudinal study of lung disease by ultrastructure defect and genotype. Am J Respir Crit Care Med. 2019;199:190-8. PMID: 30067075; PMCID: PMC6353004.
• Wallmeier J, Frank D, Shoemark A, et al. De novo mutations in FOXJ1 result in a motile ciliopathy with hydrocephalus and randomization of left/right body asymmetry. Am J Hum Genet. 2019;105:1030-39. PMID: 31630787; PMCID: PMC6849114.
• Metwally AA, Ascoli C, Ran A, et al. Pediatric lung transplantation: dynamics of the microbiome and bronchiolitis obliterans in cystic fibrosis. J Heart Lung Transplant. 2020;39:824-34. PMID: 32580896; PMCID: PMC7437357.
• Sagel SD, Kupfer O, Wagner BD, et al. Airway inflammation in children with primary ciliary dyskinesia. Ann Am Thorac Soc. 2023;20:67-74. PMCID: PMC9819265.
• Kinghorn B, Rosenfeld M, Sullivan E, et al. Airway disease in children with primary ciliary dyskinesia: impact of ciliary ultrastructure defect and genotype. Ann Am Thorac Soc. 2023;20:539-547. PMID: 36442147; PMCID: PMC10112400.
• Ringshausen FC, Shapiro AJ, Nielsen KG, et al. Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial. Lancet Respir Med. 2024;12:21-33. PMID: 37660715.